

# Srihari Gopal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/121700/publications.pdf>

Version: 2024-02-01

86  
papers

13,381  
citations

136740

32  
h-index

56606

83  
g-index

86  
all docs

86  
docs citations

86  
times ranked

19237  
citing authors

#	ARTICLE	IF	CITATIONS
1	Sex-Dependent Shared and Nonshared Genetic Architecture Across Mood and Psychotic Disorders. <i>Biological Psychiatry</i> , 2022, 91, 102-117.	0.7	61
2	A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2022, 25, 238-251.	1.0	28
3	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	13.7	929
4	A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts. <i>Biological Psychiatry</i> , 2021, 90, 611-620.	0.7	103
5	Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate. <i>Comprehensive Psychiatry</i> , 2021, 107, 152233.	1.5	5
6	Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 2239-2248.	0.8	15
7	Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. <i>CNS Drugs</i> , 2021, 35, 39-59.	2.7	67
8	Defining "Adequately Treated": A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 1-9.	1.0	3
9	Population Pharmacokinetics of Paliperidone Palmitate (Once-Monthly Formulation) in Japanese, Korean, and Taiwanese Patients With Schizophrenia. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 224-234.	0.8	5
10	Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 1093-1102.	0.8	28
11	Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 681-690.	1.0	3
12	Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 1533-1542.	1.0	14
13	Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 3197-3208.	1.0	5
14	Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532098150.	1.2	3
15	Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1365-1379.	1.0	28
16	Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 499-510.	0.9	5
17	Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 587-602.	1.0	4
18	Population-based identity-by-descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2019, 180, 223-231.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 180-182.	0.7	10
20	Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 567-574.	0.7	5
21	An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate. <i>Perspectives in Psychiatric Care</i> , 2018, 54, 530-538.	0.9	10
22	Methodological challenges in indirect treatment comparisons. <i>International Clinical Psychopharmacology</i> , 2018, 33, 213-216.	0.9	1
23	The impracticality of surgically removing intramuscular long-acting injectable antipsychotic medication. <i>American Journal of Emergency Medicine</i> , 2018, 36, 522-523.	0.7	1
24	Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2807-2816.	1.0	4
25	Maintenance dose conversion between oral risperidone and paliperidone palmitate 1-month: Practical guidance based on pharmacokinetic simulations. <i>International Journal of Clinical Practice</i> , 2018, 72, e13089.	0.8	12
26	Estimation of Genetic Correlation via Linkage Disequilibrium Score Regression and Genomic Restricted Maximum Likelihood. <i>American Journal of Human Genetics</i> , 2018, 102, 1185-1194.	2.6	119
27	Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. <i>NPJ Schizophrenia</i> , 2018, 4, 10.	2.0	24
28	Letter to the Editor: Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?. <i>Psychological Medicine</i> , 2018, 48, 2098-2099.	2.7	0
29	Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes. <i>Cell</i> , 2018, 173, 1705-1715.e16.	13.5	623
30	Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis. <i>Clinical Drug Investigation</i> , 2018, 38, 695-702.	1.1	7
31	Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	29
32	Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2017, 32, 329-336.	0.9	16
33	Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies. <i>NPJ Schizophrenia</i> , 2017, 3, 23.	2.0	27
34	Genome-wide association study of paliperidone efficacy. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 7-18.	0.7	42
35	Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study. <i>CNS Drugs</i> , 2017, 31, 797-808.	2.7	8
36	Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2193-2207.	1.0	11

#	ARTICLE	IF	CITATIONS
37	Does Half-Life Matter After Antipsychotic Discontinuation?. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e813-e820.	1.1	62
38	Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 69.	1.0	5
39	Physician and patient benefit&ndash;risk preferences from two randomized long-acting injectable antipsychotic trials. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 2127-2139.	0.8	22
40	Prospective dose selection and acceleration of paliperidone palmitate 3â€month formulation development using a pharmacometric bridging strategy. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1364-1370.	1.1	11
41	Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy. <i>International Clinical Psychopharmacology</i> , 2016, 31, 202-209.	0.9	41
42	Paliperidone palmitate: Japanese postmarketing mortality results in patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2016, 32, 1671-1679.	0.9	12
43	Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 744-745.	0.7	5
44	Benefitâ€risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia. <i>International Clinical Psychopharmacology</i> , 2016, 31, 315-322.	0.9	5
45	Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3â€month formulation in patients with schizophrenia: A phaseâ€I, singleâ€dose, randomized, openâ€label study. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 330-339.	1.0	63
46	Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of concept. <i>Nature Neuroscience</i> , 2016, 19, 420-431.	7.1	204
47	Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw018.	1.0	129
48	Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 830.	6.0	169
49	Efficacy and Safety of Paliperidone Extended Release in Adolescents With Schizophrenia: A Randomized, Double-Blind Study. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 126-137.e1.	0.3	39
50	Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 173-185.	0.7	14
51	Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. <i>American Journal of Human Genetics</i> , 2015, 97, 576-592.	2.6	1,098
52	Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia. <i>Current Medical Research and Opinion</i> , 2015, 31, 2043-2054.	0.9	28
53	Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose Study. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 548-557.	0.7	15
54	SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response. <i>Pharmacogenomics</i> , 2014, 15, 1557-1564.	0.6	6

#	ARTICLE	IF	CITATIONS
55	Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 53, 45-53.	2.5	23
56	Partitioning Heritability of Regulatory and Cell-Type-Specific Variants across 11 Common Diseases. <i>American Journal of Human Genetics</i> , 2014, 95, 535-552.	2.6	569
57	A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1048-1057.	1.0	36
58	Biological insights from 108 schizophrenia-associated genetic loci. <i>Nature</i> , 2014, 511, 421-427.	13.7	6,934
59	Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases. <i>International Journal of Clinical Practice</i> , 2014, 68, 1514-1522.	0.8	18
60	Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. <i>Annals of General Psychiatry</i> , 2013, 12, 22.	1.2	28
61	Effect of parental age on treatment response in adolescents with schizophrenia. <i>Schizophrenia Research</i> , 2013, 151, 185-190.	1.1	8
62	Risk of Cardiovascular Morbidity With Risperidone or Paliperidone Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 157-161.	0.7	28
63	Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 721.	1.0	4
64	Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1381.	1.0	21
65	An Analysis of Potentially Prolactin-Related Adverse Events and Abnormal Prolactin Values in Randomized Clinical Trials with Paliperidone Palmitate. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1322-1330.	0.9	13
66	A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 107-118.	1.0	87
67	Prolongation of Cardiac Ventricular Repolarization Under Paliperidone. <i>Journal of Cardiovascular Pharmacology</i> , 2012, 59, 298-299.	0.8	1
68	Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. <i>Schizophrenia Research</i> , 2012, 138, 29-34.	1.1	82
69	A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. <i>BMC Psychiatry</i> , 2012, 12, 26.	1.1	52
70	Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). <i>Current Medical Research and Opinion</i> , 2011, 27, 1603-1611.	0.9	37
71	Dosing and Switching Strategies for Paliperidone Palmitate. <i>CNS Drugs</i> , 2011, 25, 1.	2.7	60
72	A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 218-226.	2.5	146

#	ARTICLE	IF	CITATIONS
73	Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2011, 7, 93.	1.0	25
74	Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases. <i>Current Drug Safety</i> , 2011, 6, 43-45.	0.3	20
75	A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. <i>Journal of Psychopharmacology</i> , 2011, 25, 685-697.	2.0	93
76	A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. <i>Innovations in Clinical Neuroscience</i> , 2011, 8, 26-33.	0.1	6
77	Efficacy and Safety of Paliperidone Extended Release 1.5 mg/day-A Double-blind, Placebo- and Active-Controlled, Study in the Treatment of Patients with Schizophrenia. <i>Psychopharmacology Bulletin</i> , 2011, 44, 54-72.	0.0	8
78	Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. <i>International Clinical Psychopharmacology</i> , 2010, 25, 247-256.	0.9	133
79	A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 235-244.	0.7	170
80	Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2010, 26, 377-387.	0.9	66
81	A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia. <i>Neuropsychopharmacology</i> , 2010, 35, 2072-2082.	2.8	131
82	Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study. <i>Schizophrenia Research</i> , 2010, 116, 107-117.	1.1	225
83	Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention. <i>Current Medical Research and Opinion</i> , 2010, 26, 1471-1484.	0.9	24
84	Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1022-1031.	2.5	107
85	Symptomatic Remission in Patients with Bipolar Mania: Results from a Double-Blind, Placebo-Controlled Trial of Risperidone Monotherapy. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2007, 2, 213-224.	0.0	0
86	Symptomatic Remission in Patients With Bipolar Mania. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1016-1020.	1.1	41